Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer
about
Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cellsHistone deacetylases, microRNA and leptin crosstalk in pancreatic cancer.CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cellsChromatin remodeler mutations in human cancers: epigenetic implications.Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancerHDACs and HDAC Inhibitors in Cancer Development and Therapy.Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α.Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase.Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.Epigenetic Regulation of Autophagy: A Path to the Control of Autoimmunity
P2860
Q28533896-36C15771-322A-488D-BB70-B46342E87FB8Q33779854-CF7B27C4-54B8-4587-AFF9-C72A4ADFF4AFQ34544769-2A32C182-754F-435E-8C9F-87E6C21F2C69Q34690409-9FC4BB2C-CD4D-448B-9609-922AE470FCFBQ34734222-E77FCB95-244B-43C7-885C-837E36CB0CB2Q34808616-8773FB98-A747-45B0-8877-E1C97F7A685FQ35214924-A674755F-1350-4BFC-A40C-9EDBF348BB2AQ36843733-B7ACDCF1-13FD-479E-9FF5-E38ACCBF1F05Q37376388-4F6A69DB-080B-48D5-B473-786634EAC583Q37630747-2417678F-A931-41CA-AFA8-35AFA7AF2E50Q38261746-40514660-E69F-499F-9C53-171B8CA18770Q38748709-E72BDEA0-C57B-4628-8CCC-AA7BAA5746B7Q38947405-F6019C2B-9D03-4B7F-943A-1132302D4893Q38948573-0B8C8270-9B29-41A5-A718-6AD71DED87DBQ39037363-4BCF5B77-142D-4221-897E-847D7EE71ADAQ40951274-11280F54-672E-40D7-AFC6-B8B570347F9EQ42362715-2FB14F71-5DD0-4606-88F5-8B68B28BA2A3Q47141971-93A97047-0261-46D4-B28C-E9132B6CDF98Q47425444-3A7D063C-93BE-4654-B7FA-2586FD0F31CDQ49853764-9619AA82-257E-46D4-A7E6-4B69DA0C6554Q51034578-8F60CE0A-72DE-43C0-9E11-2DDD68D78F26Q58781739-C22C1312-BB8C-470E-A56E-EA9E0CACCD09
P2860
Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Class I and class II histone d ...... for treating pancreatic cancer
@ast
Class I and class II histone d ...... for treating pancreatic cancer
@en
Class I and class II histone d ...... for treating pancreatic cancer
@nl
type
label
Class I and class II histone d ...... for treating pancreatic cancer
@ast
Class I and class II histone d ...... for treating pancreatic cancer
@en
Class I and class II histone d ...... for treating pancreatic cancer
@nl
prefLabel
Class I and class II histone d ...... for treating pancreatic cancer
@ast
Class I and class II histone d ...... for treating pancreatic cancer
@en
Class I and class II histone d ...... for treating pancreatic cancer
@nl
P2093
P2860
P1433
P1476
Class I and class II histone d ...... for treating pancreatic cancer
@en
P2093
Chengzhi Xie
Jeffrey W Taub
Jianyun Zhao
Ramzi M Mohammad
Wenting Yun
Yingjie Guo
P2860
P304
P356
10.1371/JOURNAL.PONE.0052095
P407
P50
P577
2012-12-14T00:00:00Z